Fluid overload
Methodology & AI Transparency ⓘ
Fluid overload Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Chronic Kidney Disease & Electrolytes practice, Fluid overload (ICD-10 E87.70) is stratified through spot urine albumin-to-creatinine in Fluid overload (E87.70: ratio), pairing targeted symptom control with longitudinal Urine Albumin-to-Creatinine Ratio in Fluid overload (E87.70: (uACR)) surveillance.
- 2 Real-world patient consensus: Mapped to Chronic Kidney Disease & Electrolytes under ICD-10-CM E87.70 for Fluid overload clinical workups.
- 3 Typical cash cost range: Clinicians assessing Fluid overload focus on intrarenal RAAS activation [Fluid overload E87.70] and targeted history.
- 4 Top reported side effects / signs: Key Kidney & Renal biomarkers for Fluid overload (E87.70): eGFR (Creatinine + in Fluid overload (E87.70: Cystatin C)) & Urine Albumin-to-Creatinine Ratio in Fluid overload (E87.70: (uACR)) (< 15 mg/g (< 30 mg/g normal) (E87.70)).
Ask our AI Specialists anything about Fluid overload
What Is Fluid overload?
Within Chronic Kidney Disease & Electrolytes practice, Fluid overload (ICD-10 E87.70) is stratified through spot urine albumin-to-creatinine in Fluid overload (E87.70: ratio), pairing targeted symptom control with longitudinal Urine Albumin-to-Creatinine Ratio in Fluid overload (E87.70: (uACR)) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Fluid overload (E87.70) alters kidney & renal homeostasis through intrarenal RAAS activation [Fluid overload E87.70]; clinical remission targets Urine Albumin-to-Creatinine Ratio in Fluid overload (E87.70: (uACR)) within < 15 mg/g (< 30 mg/g normal) (E87.70).
Common Symptoms & Clinical Signs
- • Presentation of Fluid overload (E87.70): fatigue, muscle cramps, in Fluid overload (E87.70: metallic taste, or)
- • Secondary Fluid overload clinical sign: changes in urine in Fluid overload (E87.70: output volume, nocturnal)
- • Symptom flares in Fluid overload correlating with eGFR (Creatinine + in Fluid overload (E87.70: Cystatin C)) deviation outside >= 90 mL/min/1.73m2 (E87.70)
- • Functional kidney & renal impact requiring spot urine albumin-to-creatinine in Fluid overload (E87.70: ratio) evaluation (E87.70)
Fluid overload Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E87.70 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Fluid overload (E87.70: Cystatin C)) | >= 90 mL/min/1.73m2 (E87.70) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Fluid overload (E87.70: (uACR)) | < 15 mg/g (< 30 mg/g normal) (E87.70) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Fluid overload (E87.70: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.70) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Fluid overload
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Deferasirox Exjade, Jadenu • RxCUI 597768 | Iron Chelator | 87% | $0.8750 | $ 14.07 /mo |
| Deferiprone Ferriprox • RxCUI 1716264 | Iron Chelator | 75% | $1.2600 | $ 522.50 /mo |
| Deferoxamine Mesylate Desferal • RxCUI 1731350 | Iron Chelator | 93% | $0.6900 | $ 36.45 /mo |
| Exjade (Deferasirox) Exjade • RxCUI 597770 | Iron Chelator | 81% | $0.8750 | $ 28.93 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fluid overload)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Rosuvastatin and atorvastatin on kidney function:: What a 24,278-Participant Study Found Both RSV and ATV improve GFR, and ATV seems to be more effective in reducing proteinuria. Circulation journal : official journal of the Japanese Circulation Society • 2012-01-15 • Meta-Analysis | N = 24,278 | 99/100 | PMID 22382383 ↗ |
| New Insights on Benefits and safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines:: What a 300-Participant Study Found CKDB-501A is a safe and effective alternative to existing botulinum toxin products for treating moderate-to-severe glabellar lines, offering benefits of improved biocompatibility and reduced risk of allergic reactions. Journal of cosmetic dermatology • 2025-07-15 • Phase III Randomized Trial | N = 300 | 93/100 | PMID 40586136 ↗ |
| New Insights on Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular: What a 1,097-Participant Study Found A greater proportion of ranibizumab-treated eyes with nAMD gained/maintained visual acuity at SRF resolution. Ophthalmology. Retina • 2022-11-15 • Phase III Randomized Trial | N = 1,097 | 90/100 | PMID 35654363 ↗ |
| New Insights on EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE: What a 1,752-Participant Study Found More stable CST was associated with better visual outcomes at the end of treatment suggesting that CST variability may provide a more reliable prognostic marker of visual outcomes than the presence of fluid alone, with the... Retina (Philadelphia, Pa.) • 2022-03-01 • Phase III Randomized Trial | N = 1,752 | 90/100 | PMID 34923515 ↗ |
| New Insights on Identification of key symptoms impacting HRQOL in advanced kidney cell carcinoma:: What a 323-Participant Study Found These findings highlight underlying pathways contributing to HRQOL improvement in patients with aRCC receiving nivolumab plus cabozantinib. The oncologist • 2026-08-06 • Phase III Randomized Trial | N = 323 | 87/100 | PMID 42605077 ↗ |
Fluid overload Patient Community & “People Like Me” Threads
Filter Fluid overload community threads and patient logs by age, biological sex, dosage, and treatment duration.